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Hypersensitivity and streptokinase
SIR,-A natural experiment is underway in the widespread
treatment of patients with streptokinase (SK) to produce
thrombolysis after acute myocardial infarction. The SK enzymes
present in commercial products are derived from cultures of
Streptococcus equisimilis (Lancefield group C), and the side-effects
now being reported are relevant to research on streptococcal
diseases.
Dr Callan and others (Jan 13, p 106) describe delayed
hypersensitivity reactions after SK therapy. The illness in such
patients features a diffuse vasculitis with rash, fever, arthralgia,
proteinuria, haematuria, and sometimes impaired renal function.
Immediate hypersensitivity reactions are more common than
delayed reactions after SK therapy but they may be suppressed by
hydrocortisone.1 In ten patients studied by Dr Argent and Dr
Adams (Jan 13, p 106) symptomless proteinuria and haematuria
associated with coarse granular casts in the urine occurred in all
cases 4 h after SK administration, clearing by 48 h. Antibodies to
SK develop in most patients treated with SK, as reported by Dr
Jalihal and Mr Morris but their role in the above complications is
not yet clear.
A variant SK enzyme with special affinity for the glomerular
basement membrane, nephritis strain-associated protein (NSAP),
is a strong contender as the pathogenic agent in glomerulonephritis
developing after Strep pyogenes infection.2 Endostreptosin (ESS),
another candidate,3 is thought to be an intracellular precursor of
NSAP. These substances are thought to be deposited on the
basement membrane with subsequent coating by antibody and
complement, leading to the derangement of glomerular function;
high levels of antibody to NSAP, ESS, and SK are found in patients
with acute post-streptococcal nephritis 4 It is not known whether
pre-existing antibody would protect against the development of
nephritis but prospects for a vaccine have been discussed.6 Recent
isolates of Lancefield group C and G streptococci from patients
with nephritis have been shown to produce ESS or molecular
variants ofNSAP.6,7 In an intriguing case-report severe crescentic
glomerulonephritis with cutaneous purpura developed in a patient
33 days after SK therapy for acute myocardial infarction in 13 days
after an intercurrent group G streptococcal pharyngitis;8 perhaps
SK-induced antibody worsened the situation in this patient.
The "dose" of SK received by the patient in natural streptococcal
infection is likely to be much less, and delivered more slowly, than it
is in SK therapy. These factors, together with the different
biological properties of SK enzymes, might lead to different
patterns of injury to the vessel walls and glomerulus. The
hypersensitivity effects after therapeutic injection of SK might also
throw some light on the relation between streptococci and skin
diseases such as acute guttate psoriasis, erythema multiforme, and
urticaria; streptococcal products inducing vasculitis, such as SK,
might play a part in triggering these rashes.
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Cyclosporin wash for oral lichen planus
SIR,-Cyclosporin, when used systemically, has proved helpful in
lichen planus.1,2 Unfortunately, when given by this route,
cyclosporin has adverse effects that limit its use in skin diseases.3
Lichen planus affecting the oral cavity is especially difficult to treat
and remissions are short-lived even when systemic corticosteroids
and retinoids are used. Most topical agents are little more than
palliative. We have been exploring the value of topical cyclosporin
in patients with oral lichen planus.
Five women and one man aged 44-76 (mean 54) years with
biopsy proven oral lichen planus were enrolled. They had had the
disease for 2 years on average (range 3 months to 5 years). Topical
medication was halted 2 weeks, and systemic medications 4 weeks,
before the start of the study. The patients gave informed consent
and the study was approved by the University of Michigan
institutional review board.
In an open study patients used cyclosporin 100 mg/ml (the
standard formulation for oral systemic administration). They were
told to swish 5 ml (500 mg) in the oral cavity and to spit it out after
5 min. No eating or drinking was then permitted for 30 min. The
treatment was repeated three times daily for 8 weeks. The same
physician evaluated the patient before therapy and then in weeks 1,
2, 3, 4, 6, and 8 on a scale from 0 (no clinical disease) to 3 (severe
disease). Erythema, and reticulation were assessed on this scale for
every lesion erosion. A mean erosion score was calculated by
summing erosion scores and dividing by the number of lesions with
erosion. This was done for erythema and reticulation also. The
patients graded their symptoms on a scale of 0 (no pain) to 3 (severe
discomfort).
Whole blood cyclosporin levels were measured by high
performance liquid chromatography (HPLC) 1-4 h after swishing
and expectorating and routine laboratory tests were done at every
visit. Representative lesions were photographed at baseline, after 4
weeks of therapy, and upon completion of the study. In four
patients, 4 mm punch biopsies were done on affected buccal mucosa
before and at the end of cyclosporin treatment. Immunoperoxidase
staining4 of 5 pm cryostat sections was performed with a ’Vectastain
ABC’ kit (Vector Laboratories) and the following panel of
monoclonal antibodies: RR 1/1 (from Dr T. Springer, Dana Farber
Cancer Institute, Boston) for ICAM-1, L243 (Becton Dickinson)
for HLA-DR; LeulO (Becton Dickinson) for HLA-DQ; and Tl 1
(Coulter Immunology) for CD2.
All patients improved in all categories. Erythema scores fell from
2-0 (0-2) at baseline to 0-1 (0-0) after 8 weeks of topical cyclosporin
(p=0-03); erosion scores fell from 2-4 (0-5) to 0-3 (0-2) (not
significant, n &mdash; 4 only), and reticulation scores decreased from 1 -7
(0-2) to 0-7 (0-2) (p=0&deg;03). All six patients experienced significant
discomfort before therapy with an average pain score of 22 (0-2).
After treatment the pain score was only 0- (0-1) (p = 0-03) with
complete relief noted by four patients. All six noted transient
burning of the mucosal surfaces while swishing the medication.
Four reported slight precipitation, resulting in waxy particles which
could easily be spat out.
In four patients, cyclosporin levels in whole blood were
undetectable (less than 20 ng/ml) or low (30-60 ng/ml); in the other
two peaks of 176 and 184 ng/ml were recorded, but in only one of
these were moderate concentrations (60-90 ng/ml) persistent.
Cyclosporin levels did not correlate with clinical response.
Laboratory results did not change signficantly.
Before cyclosporin therapy keratinocytes of oral lichen planus
expressed both ICAM-1 and HLA-DR but not HLA-DQ. In
keratinocytes at the end of cyclosporin treatment ICAM-1
expression was virtually undetectable with HLA-DR expression
was moderately reduced. The CD2 T-lymphocyte infiltrate in the
epidermis (by more than half) and in the dermis (by about
one-third) was much reduced, and HLA-DR expression by
T-lymphocytes in epidermis and dermis decreased in proportion.
5 months after completion of the study five patients were
re-examined. No new lesions were detected and old lesions that had
not completely resolved with cyclosporin remained unchanged. All
six patients expressed a preference for the oral swish method over
topical steroids applied previously. Spontaneous remissions in oral
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ulcerative lichen planus is rares and we are confident that the
clearing of active lesions in these six patients represents a response to
cyclosporin.
Grattan et al treated four patients with cutaneous hypertrophic
lichen planus with topical cyclosporin under occlusion and reported
flattening of lesions and in another study, four patients with oral
lichen planus who applied cyclosporin to lesions with their fingers
obtained partial resolution of their ulcers 7 However, absorption of
drug through the skin is likely to be much less than absorption
through oral mucosa. The mechanism of action of cyclosporin in
lichen planus is unknown. However, it selectively inhibits
production of interferon-y, a lymphokine thought to be critical in
the pathogenesis of lichen planus. Produced by activated T
lymphocytes, interferon-y induces the expression of ICAM-1 and
HLA-DR by keratinocytes.8 These surface molecules and their
interaction with interferon-y trigger an influx of T lymphocytes to
the skin where an inflammatory reaction is established with
subsequent tissue destruction.9
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Hypophosphataemic rickets and final
height
SIR,&mdash;Professor Stickler and Dr Morgenstern (Oct 14, p 902)
suggest that treatment of X-linked hypophosphataemic rickets with
vitamin D (or one of its active derivatives) in pharmacological doses
does not affect ultimate height and that clinical trials should
therefore be undertaken. Our experience differs.
We had stricter diagnostic criteria than theirs (which may have
included other forms of metabolic rickets) and we reported from
University College Hospital the adult height of 8 patients whose
vitamin D treatment was supervised by us.1 With Stickler and
Morgenstern’s2 American criteria, this value was 2-10 (SD 0-69)
standard deviations below the mean. A further 8 patients, all with
positive family histories, who had been under our supervision since
before the age of 5 years, are now adults. Their mean height is 2-08
(0-76) SD below the American value (figure). The difference
between our patients and those of Stickler and Morgenstern is
probably an underestimate since heights of healthy British men and
women on the 50th centile3 are, respectively, 1-7 and 0-5 cm (0-37
and 0-08 American SD) below those of Americans. The mean
heights of our 10 men and 6 women (161-9 [SD 4-2] cm and 150-3
[5-7] cm, respectively) are almost on the 3rd (British) centile. Only 6
Adult height of patients treated continuously at the Mayo
Clinic (from Stickler and Morgernstern) and at UCH/RNOH.
of our 16 patients received phosphate supplements, for a mean of 5 ’7
years, without detectable change in growth rate.
7 of 10 children aged 3-13 years currently under follow-up had
known family histories at birth and were diagnosed and receiving
treatment by the age of 20 months. All 7 are now on or above the
25th centile.
Our 16 adults have had a total of 4 osteotomies, compared with 88
osteotomies among 34 patients in the Mayo Clinic series (Chi-
squared test, p < 0-001). Only 2 of our 10 children, who were
diagnosed late, may eventually need osteotomy.
Differences between the results of "vitamin D treatment" in the
two groups can be explained either by greater severity of the disease
in the USA or by differences in management and therefore of
patient selection. We agree that occasionally male patients may be
only mildly affected for uncertain reasons which could include
variable deletions in the short arm of the X chromosome. But in
most patients X-linked rickets needs careful tailoring of
pharmacological vitamin D (or calcitriol or alfacalcidol) dose to
individual requirements from the earliest possible age until growth
ceases-on the basis of growth, radiographic appearances, serum
calcium, and alkaline phosphatase.! Stickler and Morgenstern may
have shown only that serious delay in diagnosis and/or less stringent
medical management is not much better than no treatment at all.
Any controlled trial of vitamin D therapy such as they seek would, at
the least, pose serious ethical questions.
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SiR,&mdash;Professor Stickler and Dr Morgenstem’s retrospective study
of 52 patients with X-linked hypophosphataemic rickets, treated
with high doses of vitamin D, vitamin D plus phosphate
supplements, or calcitriol plus phosphate, or untreated, shows that
final height was not affected by the treatment regimen or sex. A
significant negative correlation was observed with the number of
osteotomies. Vitamin D intoxication led to irreversible severe renal
failure in 3 patients. Stickler and Morgenstern conclude that "until
a treatment is established as effective in controlled trials, it may be
better that these patients remain untreated".
